ST2L Transmembrane Receptor Expression: An Immunochemical Study on Endarterectomy Samples
暂无分享,去创建一个
A. Marzullo | A. Zito | F. Devito | P. Scicchitano | M. Ciccone | F. Ambrosi | F. Manca | D. Angiletta | Mirjam Inchingolo | Mirjam Inchingolo | Fiorella Devito | Pietro Scicchitano
[1] Cheuk-Man Yu,et al. IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study. , 2015, Seminars in arthritis and rheumatism.
[2] Daniel Levy,et al. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective , 2014, The Lancet.
[3] M. Iacoviello,et al. A Novel Cardiac Bio-Marker: ST2: A Review , 2013, Molecules.
[4] P. Quax,et al. Soluble ST2 levels are not associated with secondary cardiovascular events and vulnerable plaque phenotype in patients with carotid artery stenosis. , 2013, Atherosclerosis.
[5] Fan Wang,et al. The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population. , 2013, American journal of human genetics.
[6] C. Ayers,et al. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. , 2013, Clinical chemistry.
[7] M. Vatn,et al. Interleukin‐33 drives a proinflammatory endothelial activation that selectively targets non‐quiescent cells , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[8] G. Keren,et al. Interleukin-33 augments Treg cell levels: a flaw mechanism in atherosclerosis. , 2012, The Israel Medical Association journal : IMAJ.
[9] A. Lusis. Genetics of atherosclerosis. , 2012, Trends in genetics : TIG.
[10] Enrico Ascher,et al. Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. , 2011, Journal of vascular surgery.
[11] G. Maurer,et al. Interleukin-33 Induces Expression of Adhesion Molecules and Inflammatory Activation in Human Endothelial Cells and in Human Atherosclerotic Plaques , 2011, Arteriosclerosis, Thrombosis and Vascular Biology.
[12] P. Libby,et al. Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.
[13] Ashley M. Miller,et al. IL-33 Reduces Macrophage Foam Cell Formation , 2010, The Journal of Immunology.
[14] I. McInnes,et al. Disease-associated functions of IL-33: the new kid in the IL-1 family , 2010, Nature Reviews Immunology.
[15] S. Nakae,et al. IL-33 and IL-33 receptors in host defense and diseases. , 2010, Allergology international : official journal of the Japanese Society of Allergology.
[16] M. Kolácková,et al. The counter-regulation of atherogenesis: a role for interleukin-33. , 2010, Acta medica.
[17] M. Hayakawa,et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells , 2010, Molecular and Cellular Biochemistry.
[18] I. McInnes,et al. IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation1 , 2009, The Journal of Immunology.
[19] Qutayba Hamid,et al. Increased Expression of IL-33 in Severe Asthma: Evidence of Expression by Airway Smooth Muscle Cells1 , 2009, The Journal of Immunology.
[20] E. Weinberg. ST2 protein in heart disease: from discovery to mechanisms and prognostic value. , 2009, Biomarkers in medicine.
[21] Bo-Jeong Pyun,et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. , 2009, Blood.
[22] J. Pollheimer,et al. Vascular Biology , Atherosclerosis and Endothelium Biology Nuclear Interleukin-33 Is Generally Expressed in Resting Endothelium but Rapidly Lost upon Angiogenic or Proinflammatory Activation , 2010 .
[23] Richard T. Lee,et al. The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.
[24] R. Bush,et al. Management of atherosclerotic carotid artery disease: clinical practice guidelines of the Society for Vascular Surgery. , 2008, Journal of vascular surgery.
[25] Ashley M. Miller,et al. IL-33 reduces the development of atherosclerosis , 2008, The Journal of experimental medicine.
[26] D. Ribatti,et al. Inflammatory angiogenesis in atherogenesis—a double-edged sword , 2008, Annals of medicine.
[27] Renu Virmani,et al. Pathology of the vulnerable plaque. , 2007, Journal of the American College of Cardiology.
[28] Philippe Douek,et al. The Vulnerable Carotid Artery Plaque: Current Imaging Methods and New Perspectives , 2005, Stroke.
[29] J Fernando Bazan,et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.
[30] J. Goldin,et al. Determinants of plaque instability in atherosclerotic vascular disease. , 2005, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[31] P. Shah,et al. Mechanisms of plaque vulnerability and rupture. , 2003, Journal of the American College of Cardiology.
[32] H. C. Stary,et al. Natural history and histological classification of atherosclerotic lesions: an update. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[33] K. Williams,et al. Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.
[34] A E Becker,et al. Atherosclerotic plaque rupture--pathologic basis of plaque stability and instability. , 1999, Cardiovascular research.
[35] P. Libby,et al. The unstable atheroma. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[36] W D Wagner,et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. , 1995, Arteriosclerosis, thrombosis, and vascular biology.